Skip to main content
Fig. 3 | Molecular Medicine

Fig. 3

From: Subunits of ARID1 serve as novel biomarkers for the sensitivity to immune checkpoint inhibitors and prognosis of advanced non-small cell lung cancer

Fig. 3

Novel nomogram to predict the prognosis of immune checkpoint inhibitor (ICI) treatment. a The survival curves for ICIs-treated patients based on the EGFR mutational status; b. The survival curves for ICIs-treated patients based on the ARID1B mutational status; c. The survival curves for ICIs-treated patients based on PD-L1 expression; d. The survival curves for ICIs-treated patients based on the tumor mutational burden (TMB); e. The survival curves for ICIs-treated patients based on treatment lines; f. The survival curves for ICIs-treated patients based on smoking history; g. The novel nomogram based on patient information to predict the prognosis of ICI treatment; h. The calibration plot for the nomogram

Back to article page

Molecular Medicine

ISSN: 1528-3658